

## MIRA INFORM REPORT

<b>Report No. :</b>	530001
<b>Report Date :</b>	18.09.2018

### IDENTIFICATION DETAILS

<b>Name :</b>	AMNEAL PHARMACEUTICALS LLC
<b>Registered Office :</b>	Corporation Trust Center 1209 Orange St, Wilmington, Delaware
<b>Country :</b>	United States
<b>Financials (as on) :</b>	31.03.2018 [Subject's and its subsidiaries]
<b>Date of Incorporation :</b>	2002
<b>Legal Form :</b>	Limited Liability Company
<b>Line of Business :</b>	Subject manufactures oral solid dosage form for generic
<b>No. of Employees :</b>	1900

**DISCLAIMER :** This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

**RATING & COMMENTS**

(Mira Inform has adopted New Rating mechanism w.e.f. 23<sup>rd</sup> January 2017)

**MIRA's Rating :**

A

Credit Rating	Explanation	Rating Comments
A	Acceptable Risk	Business dealings permissible with moderate risk of default

<b>Status :</b>	Good
<b>Payment Behaviour :</b>	No Complaints
<b>Litigation :</b>	Exist

**NOTES :**

Any query related to this report can be made on e-mail : [infodept@mirainform.com](mailto:infodept@mirainform.com) while quoting report number, name and date.

**ECGC Country Risk Classification List**

Country Name	Previous Rating (31.12.2017)	Current Rating (01.04.2018)
United States	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

**DISCLAIMER :** This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

**UNITED STATES - ECONOMIC OVERVIEW**

The US has the most technologically powerful economy in the world, with a per capita GDP of \$59,500. US firms are at or near the forefront in technological advances, especially in computers, pharmaceuticals, and medical, aerospace, and military equipment; however, their advantage has narrowed since the end of World War II. Based on a comparison of GDP measured at purchasing power parity conversion rates, the US economy in 2014, having stood as the largest in the world for more than a century, slipped into second place behind China, which has more than tripled the US growth rate for each year of the past four decades.

In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, businesses face higher barriers to enter their rivals' home markets than foreign firms face entering US markets.

Long-term problems for the US include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.

The onrush of technology has been a driving factor in the gradual development of a "two-tier" labor market in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers such as China, has put additional downward pressure on wages and upward pressure on the return to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income.

Imported oil accounts for more than 50% of US consumption and oil has a major impact on the overall health of the economy. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at \$840 billion in 2008. Because the US economy is energy-intensive, falling oil prices since 2013 have alleviated many of the problems the earlier increases had created.

The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the US into a recession by mid-2008. GDP contracted until the third quarter of 2009, the deepest and longest downturn since the Great Depression. To help stabilize financial markets, the US Congress established a \$700 billion Troubled Asset Relief Program in October 2008. The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009, Congress passed and former President Barack OBAMA signed a bill providing an additional \$787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the Federal Government reduced the growth of spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries.

Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through FY 2018, the direct costs of the wars will have totaled more than \$1.9 trillion, according to US Government figures.

In March 2010, former President OBAMA signed into law the Patient Protection and Affordable Care Act (ACA), a health insurance reform that was designed to extend coverage to an additional 32 million Americans by 2016,

through private health insurance for the general population and Medicaid for the impoverished. Total spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.

In July 2010, the former president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight.

The Federal Reserve Board (Fed) announced plans in December 2012 to purchase \$85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short-term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. The Fed ended its purchases during the summer of 2014, after the unemployment rate dropped to 6.2%, inflation stood at 1.7%, and public debt fell below 74% of GDP. In December 2015, the Fed raised its target for the benchmark federal funds rate by 0.25%, the first increase since the recession began. With continued low growth, the Fed opted to raise rates several times since then, and in December 2017, the target rate stood at 1.5%.

In December 2017, Congress passed and President Donald TRUMP signed the Tax Cuts and Jobs Act, which, among its various provisions, reduces the corporate tax rate from 35% to 21%; lowers the individual tax rate for those with the highest incomes from 39.6% to 37%, and by lesser percentages for those at lower income levels; changes many deductions and credits used to calculate taxable income; and eliminates in 2019 the penalty imposed on taxpayers who do not obtain the minimum amount of health insurance required under the ACA. The new taxes took effect on 1 January 2018; the tax cut for corporations are permanent, but those for individuals are scheduled to expire after 2025. The Joint Committee on Taxation (JCT) under the Congressional Budget Office estimates that the new law will reduce tax revenues and increase the federal deficit by about \$1.45 trillion over the 2018-2027 period. This amount would decline if economic growth were to exceed the JCT's estimate.

Source : CIA

## **STATUTORY INFORMATION**

<b>Legal Name</b>	AMNEAL PHARMACEUTICALS LLC
<b>Trade Name</b>	AMNEAL
<b>ID</b>	ID
<b>ID Details</b>	3809030
<b>Creation Date</b>	2002
<b>Incorporation Date</b>	6/15/2004
<b>Legal Address</b>	CORPORATION TRUST CENTER 1209 ORANGE ST, Wilmington, DELAWARE, USA
<b>Operative Address</b>	400 Crossing Boulevard Floor 3 Bridgewater, NJ 08807, USA
<b>Telephone</b>	(908) 947-3120
<b>Fax</b>	NA
<b>Legal Form</b>	LIMITED LIABILITY COMPANY
<b>E-Mail</b>	Sales@amneal.com
<b>Registered In</b>	DELAWARE
<b>Website</b>	www.amneal.com
<b>Contact</b>	Robert Stewart - President
<b>Staff</b>	1900
<b>Activity</b>	SIC Code: 2834, Pharmaceutical Preparations NAICS Code: 325412, Pharmaceutical Preparation Manufacturing

## **BANKS**

<b>Name of Bank</b>	<b>Reported Amount</b>
Bank of America	
CFC INVESTMENT COMPANY	
PNC BANK, NATIONAL ASSOCIATION	

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Description -

## **HISTORY**

History

Amneal Pharmaceuticals LLC was founded in 2002. The transactions pursuant to the Business Combination Agreement, dated as of October 17, 2017, as amended, by and among the Company, Impax Laboratories, LLC, K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, were consummated on May 4, 2018, and each of Impax and Amneal became subsidiaries of the Company Amneal Pharmaceuticals, Inc., a Delaware corporation.

Key Developments

NA

Parent Company

Amneal Pharmaceuticals LLC operates as a subsidiary of:  
Amneal Pharmaceuticals Inc  
400 Crossing Boulevard  
3rd Floor  
Bridgewater, NJ 08807  
United States

## **PRINCIPAL ACTIVITY**

General Description

Amneal Pharmaceuticals, L.L.C. manufactures oral solid dosage form for generic pharmaceutical products.

Service/Product Description

The company offers generic pharmaceutical products including Sectral, Tylenol, Ventolin, Lotronex, Abilify, Lotensin, Relpax, Motrin, and other pharmaceuticals.

Sales

Wholesale

Operations Area

National

Imports From

India, Germany

Employees

1900 employees

Payments With Suppliers

No complaints

### **BRANDS**

Brand

Comments

Amneal -

**CLIENTS**

Name of Client	Country	Comments
----------------	---------	----------

There are not informed clients

<b>Comments</b>	The company offers its products to retailers.
-----------------	---

**SUPPLIERS**

Supplier Name	Country	Comments
---------------	---------	----------

Amneal Pharmaceutical Co India Priv	India	-
-------------------------------------	-------	---

Ipt Pharma Trading Gmbh	Germany	-
-------------------------	---------	---

AMNEAL PHARMACEUTICALS PRIVATE LIM	India	-
------------------------------------	-------	---

<b>Comments</b>	-
-----------------	---

**LOCATION**

<b>Headquarters</b>	400 Crossing Boulevard Floor 3 Bridgewater, NJ 08807, USA
<b>Branches</b>	118 BEAVER TRL GLASGOW, KY, 42141-1273 United States 50 HORSEBLOCK RD BROOKHAVEN, NY, 11719-9509 United States 360 MORELAND RD STE C, COMMACK, NY, 11725-5707 United States 1 MURRAY RD, EAST HANOVER, NJ, 07936-2205 United States

**GROUP STRUCTURE AND SUBSIDIARY COMPANIES**

<b>Listed at the stock exchange</b>	NO
-------------------------------------	----

<b>Capital</b>	NA
----------------	----

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

<b>Shareholders (%)</b>	Amneal Pharmaceuticals LLC operates as a subsidiary of: Amneal Pharmaceuticals Inc 400 Crossing Boulevard 3rd Floor Bridgewater, NJ 08807 United States
<b>Management</b>	Chirag Patel - President
<b>Related Companies</b>	Amneal Biosciences LLC 400 Crossing Blvd FI 3 Bridgewater, NJ 08807 United States  Amedra Pharmaceuticals LLC 2 Walnut Grove Drive Suite 190 Horsham, PA 19044-7707 United States  Asana BioSciences, LLC 400 Crossing Boulevard Bridgewater, NJ 08807 United States  Amneal Pharmaceuticals of New York, LLC 85 Adams Avenue Hauppauge, NY 11788 United States

## **FINANCIAL INFORMATION**

**General Description** We attach latest financial figures for the subject.

## **LEGAL FILINGS**

**Lawsuits** SYMED LABS LIMITED et al v. AMNEAL PHARMACEUTICALS LLC et al  
Plaintiff: SYMED LABS LIMITED and HETERO USA, INC.  
Defendant: AMNEAL PHARMACEUTICALS LLC and RAKS PHARMA PRIVATE LIMITED  
Case Number: 2:2018cv13628  
Filed: September 6, 2018

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Court: New Jersey District Court  
Nature of Suit: Patent  
Cause of Action: 35:271  
Jury Demanded By: Plaintiff

Celgene Corporation v. Amneal Pharmaceuticals LLC  
Plaintiff: Celgene Corporation  
Defendant: Amneal Pharmaceuticals LLC  
Case Number: 1:2018cv01032  
Filed: July 12, 2018  
Court: Delaware District Court  
Office: Wilmington Office  
County: New Castle  
Presiding Judge: Richard G Andrews  
Nature of Suit: Patent - Abbreviated New Drug  
Application(ANDA)  
Cause of Action: 35:271  
Jury Demanded By: None

CELGENE CORPORATION v. AMNEAL  
PHARMACEUTICALS LLC  
Plaintiff: CELGENE CORPORATION  
Defendant: AMNEAL PHARMACEUTICALS LLC  
Case Number: 3:2018cv11358  
Filed: July 3, 2018  
Court: New Jersey District Court  
Office: Trenton Office  
County: Somerset  
0 Judge: Douglas E Arpert  
1 Judge: Michael A Shipp  
Nature of Suit: Patent - Abbreviated New Drug  
Application(ANDA)  
Cause of Action: 15:1126  
Jury Demanded By: None

ELI LILLY AND COMPANY et al v. AMNEAL  
PHARMACEUTICALS LLC  
Plaintiff: ELI LILLY AND COMPANY and ICOS  
CORPORATION  
Defendant: AMNEAL PHARMACEUTICALS LLC  
Case Number: 2:2018cv09071  
Filed: May 10, 2018  
Court: New Jersey District Court  
Office: Newark Office  
County: Somerset  
Referring Judge: Cathy L. Waldor  
Presiding Judge: William H. Walls  
Nature of Suit: Patent - Abbreviated New Drug  
Application

Cause of Action: 35:271  
Jury Demanded By: None

Noven Pharmaceuticals, Inc. v. Amneal  
Pharmaceuticals LLC  
Plaintiff: Noven Pharmaceuticals, Inc.  
Defendant: Amneal Pharmaceuticals LLC  
Counter\_claimant: Amneal Pharmaceuticals LLC  
Counter\_defendant: Noven Pharmaceuticals, Inc.  
Thirdparty\_defendant: Hisamitsu Pharmaceutical Co.  
Inc.  
Thirdparty\_plaintiff: Amneal Pharmaceuticals LLC  
Case Number: 1:2018cv00699  
Filed: May 8, 2018  
Court: Delaware District Court  
Office: Wilmington Office  
County: New Castle  
Presiding Judge: Leonard P. Stark  
Nature of Suit: Patent - Abbreviated New Drug  
Application  
Cause of Action: 35:271  
Jury Demanded By: None

SENJU PHARMACEUTICAL CO., LTD. et al v.  
AMNEAL PHARMACEUTICALS LLC et al  
Plaintiff: SENJU PHARMACEUTICAL CO., LTD.,  
BAUSCH & LOMB INCORPORATED and BAUSCH &  
LOMB PHARMA HOLDINGS CORP.  
Defendant: AMNEAL PHARMACEUTICALS LLC and  
AMNEAL PHARMACEUTICALS INDIA PVT. LTD.  
Case Number: 3:2018cv05571  
Filed: April 5, 2018  
Court: New Jersey District Court  
Office: Trenton Office  
County: Somerset  
Referring Judge: Tonianne J. Bongiovanni  
Presiding Judge: Brian R. Martinotti  
Nature of Suit: Patent - Abbreviated New Drug  
Application  
Cause of Action: 35:271  
Jury Demanded By: None

**Trademarks**

AMNEAL  
Manufacturing pharmaceutical preparations to the order  
and specification of others  
Owned by: AMNEAL PHARMACEUTICALS, LLC  
Serial Number: 78613136

PYRIDIDIUM  
MEDICINES FOR USE IN GERM INFECTIONS AND

**AS AN ANTISEPTIC**

Owned by: AMNEAL PHARMACEUTICALS, LLC  
Serial Number: 71272349

**REPREXAIN**

PHARMACEUTICALS, NAMELY, ANALGESICS  
Owned by: AMNEAL PHARMACEUTICALS LLC  
Serial Number: 76584625

**AMNEAL PHARMACEUTICALS**

Full line of prescription and over-the-counter  
pharmaceutical preparations for humans  
Owned by: Amneal Pharmaceuticals, LLC  
Serial Number: 85377805

**LOPREEZA**

Hormone preparations for hormone replacement  
therapy for treatment of women in menopause  
Owned by: Amneal Pharmaceuticals LLC  
Serial Number: 86321948

**Pharmaceutical Compositions Of Carvedilol Salts And  
Process For Preparation Thereof**

Publication number: 20140044781

Abstract: The present invention relates provides  
pharmaceutical compositions comprising an  
amorphous carvedilol salt and one or more  
pharmaceutically acceptable excipients, wherein the  
amorphous carvedilol salt is formed in situ during the  
preparation of the pharmaceutical composition. The  
amorphous carvedilol salt is preferably an amorphous  
carvedilol phosphate salt. The pharmaceutical  
compositions can be prepared by providing one or  
more inert cores; contacting the core or cores with a  
solution or a dispersion comprising carvedilol, an acid  
component and optionally a binder, in a solvent;  
removing the solvent; and optionally coating the core or  
cores with an extended release composition. Preferred  
pharmaceutical compositions contain both immediate-  
release pellets and at least one population of extended-  
release pellet.

Type: Application

Filed: October 21, 2013

Publication date: February 13, 2014

Applicant: Amneal Pharmaceuticals, LLC

Inventors: Jatin Desai, Vipul Rasikbhai Gajjar, Gaurav  
Navinbhai Mistry, Parva Yogeshchandra Purohit

**Pharmaceutical Compositions Of Carvedilol Salts And  
Process For Preparation Thereof**

**Patents Registered**

Publication number: 20110229564

Abstract: The present invention relates provides pharmaceutical compositions comprising an amorphous carvedilol salt and one or more pharmaceutically acceptable excipients, wherein the amorphous carvedilol salt is formed in situ during the preparation of the pharmaceutical composition. The amorphous carvedilol salt is preferably an amorphous carvedilol phosphate salt. The pharmaceutical compositions can be prepared by providing one or more inert cores; contacting the core or cores with a solution or a dispersion comprising carvedilol, an acid component and optionally a binder, in a solvent; removing the solvent; and optionally coating the core or cores with an extended release composition. Preferred pharmaceutical compositions contain both immediate-release pellets and at least one population of extended-release pellet.

Type: Application

Filed: March 18, 2011

Publication date: September 22, 2011

Applicant: Amneal Pharmaceuticals, L.L.C.

Inventors: Jatin Desai, Vipul Rasikbhai Gajjar, Gaurav Navinbhai Mistry, Parva Yogeshchandra Purohit

Stabilization of moisture-sensitive drugs

Patent number: 9629805

Abstract: Described are stability-enhancing formulations of drugs that are sensitive to moisture. The formulations comprise co-granulates containing a moisture-sensitive drug and an excipient selected from fructose, xylitol, maltitol, and mixtures thereof. Also described are methods of producing a pharmaceutical tablet. The method comprises forming a blend of a moisture-sensitive drug and a first excipient selected from fructose, xylitol, maltitol, and mixtures thereof; spraying the blend with water to produce granules; drying and milling the granules; mixing a second excipient with the granules; and compressing into tablets.

Type: Grant

Filed: March 7, 2014

Date of Patent: April 25, 2017

Assignee: Amneal Pharmaceuticals LLC

Inventors: Marianthi Karakatsani, Anita Kumar, Devjibhai D. Kumbhani, Pallapalayam M. Thangamathesvaran

Process for the preparation of rivaroxaban

Patent number: 9598403

Abstract: Described is an improved, industrially feasible and environmental friendly process for the preparation of Rivaroxaban. Also described are novel compounds which may be used as intermediates in preparation of Rivaroxaban.

Type: Grant

Filed: August 19, 2014

Date of Patent: March 21, 2017

Assignee: Amneal Pharmaceuticals LLC

Inventors: Agarwal Virendra Kumar, Upadhyay Ashish Rameshchandra, Thumar Nilesh Mansukhlal, Vala Hardevsinh Kanaksinh

Process for preparation of saxagliptin and its hydrochloride salt

Patent number: 9416105

Abstract: Described is an improved and industrially feasible process for the preparation of Saxagliptin or its hydrochloride salt. Also described are the novel intermediates and their use in the preparation of Saxagliptin or its hydrochloride salt.

Type: Grant

Filed: August 28, 2014

Date of Patent: August 16, 2016

Assignee: Amneal Pharmaceuticals LLC

Inventors: Agarwal Virendra Kumar, Siddiqui Arif Badrulhusan, Kataria Lalit Keshav, Maheta Abhay Subodhbhai, Butani Pankaj Changanbhai, Patil Shashikant Prabhakarrrao, Patil Tushar Yashwant, Deore Ganesh Suryakant, Pansuriya Ketan Jahyantibhai, Patel Hitesh Sureshbhai, Sondharava Lalit Badhabhai

No records found.

#### Renewals

#### UCC (Uniform Commercial Code)

Debtor Names: AMNEAL PHARMACEUTICALS LLC  
75 ADAMS AVE, HAUPPAUGE, NY 11788, USA  
Secured Party Names: CFC INVESTMENT COMPANY  
PO BOX 145496, CINCINNATI, OH 45250, USA  
File no.: 200904270240052 File Date: 04/27/2009  
Lapse Date: 04/27/2014 Filing Type: Financing Statement

Debtor Names: AMNEAL PHARMACEUTICALS LLC 4  
MADISON ROAD, UNIT E, FAIRFIELD, NJ 07004,  
USA  
Secured Party Names: PNC BANK, NATIONAL  
ASSOCIATION, FOR ITSELF AND AS AGENT 2  
NORTH LAKE AVENUE, SUITE 440, PASADENA, CA

91101, USA

File no.: 200906080329080 File Date: 06/08/2009  
Lapse Date: 06/08/2014 Filing Type: Financing  
Statement

File no.: 201012200686761 File Date: 12/20/2010  
Lapse Date: 06/08/2014 Filing Type: Termination

File no.: 201012206246246 File Date: 12/20/2010  
Lapse Date: 06/08/2014 Filing Type: Termination

The company is not listed in the OFAC list.

OFAC Sanctions List Search

## **SUMMARY**

Summary

Founded in 2002, Amneal Pharmaceuticals LLC is an organization in the Pharmaceutical Industry headquartered in Bridgewater, NJ. The company has 1900 regular employees and shows positive profitability in its last financial figures. It operates nationally, mainly importing from India and Germany. It is ACTIVE in business with no negative records.

## **RISK INFORMATION**

Debts	Controlled
Payments	No complaints
Cash Flow	Normal
State	Active

## **INTERVIEW**

First Name	NA
Position	NA
Comments	She confirmed the name of the company. However, she was reluctant to provide any further information.

**FOREIGN EXCHANGE RATES**

Currency	Unit	Indian Rupees
US Dollar	1	INR 72.55
UK Pound	1	INR 94.94
Euro	1	INR 84.40
USD	1	INR 72.80

**Note :** Above are approximate rates obtained from sources believed to be correct

**INFORMATION DETAILS**

Analysis Done by :	PRI
Report Prepared by :	SYL

**DISCLAIMER :** This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

**RATING EXPLANATIONS**

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)

**DISCLAIMER** : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.